Invivyd (NASDAQ:IVVD) Stock Price Up 7.2%

Invivyd, Inc. (NASDAQ:IVVD) was up 7.2% during mid-day trading on Wednesday . The company traded as high as $1.36 and last traded at $1.34. Approximately 399,155 shares were traded during trading, a decline of 45% from the average daily volume of 728,513 shares. The stock had previously closed at $1.25.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Guggenheim raised Invivyd from a “neutral” rating to a “buy” rating and set a $9.00 target price on the stock in a research note on Friday, April 5th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Invivyd in a research report on Friday, May 24th.

Invivyd Stock Performance

The stock’s 50 day moving average price is $1.47 and its 200-day moving average price is $2.86. The company has a market cap of $157.50 million, a PE ratio of -0.71 and a beta of 0.66.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.13. On average, analysts anticipate that Invivyd, Inc. will post -0.6 EPS for the current year.

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 112,381 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $1.66, for a total value of $186,552.46. Following the transaction, the director now owns 4,688,079 shares in the company, valued at $7,782,211.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 17.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Invivyd during the first quarter valued at approximately $56,000. Tidal Investments LLC purchased a new position in shares of Invivyd in the first quarter worth $126,000. Chase Investment Counsel Corp bought a new position in shares of Invivyd during the first quarter valued at $271,000. Jacobs Levy Equity Management Inc. boosted its position in shares of Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after buying an additional 77,603 shares during the last quarter. Finally, a16z Perennial Management L.P. bought a new stake in Invivyd in the 4th quarter worth about $315,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.